Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT05128097 Recruiting - Geriatric Syndromes Clinical Trials

Preventive Approach for the Management of the Main Geriatric Risks

Ger-e-Tec
Start date: June 1, 2020
Phase:
Study type: Observational

Nowadays, EHPAD residents are polypathological (cognitive and psycho-behavioral pathologies, undernutrition, IC, diabetes, COPD, IR, etc.) and multi-medicated. From a medical point of view, this implies the need for regular monitoring and a high level of medical or even multidisciplinary expertise for the healthcare team. The objective of the GER-e-TEC ™ project is to provide these complex patients with telemedicine tools allowing protocolized and personalized, non-intrusive monitoring. The GER-e-TEC ™ project more specifically takes into account the significant issues in nursing homes of aging residents with the main geriatric syndromes (fall, undernutrition, cognitive-behavioral disorders, iatropathogeny, etc.) The objective of the work undertaken is to develop a codified preventive approach for the management of the main geriatric risks, in order to avoid the occurrence of an acute decompensation factor in the elderly.

NCT ID: NCT05127616 Recruiting - Chronic Pain Clinical Trials

EPPIC: Easing Pelvic Pain Interventions Clinical Research Program

EPPIC
Start date: August 10, 2022
Phase: N/A
Study type: Interventional

The EPPIC (Easing Pelvic Pain Interventions Clinical Research Program) study evaluates an ultra-brief, 4 session cognitive behavioral pain treatment transdiagnostic in design for urologic chronic pain syndrome (UCPPS) with clinical and practical advantages over existing behavioral therapies whose length and focus limits their adoption by clinicians and coverage for mechanistically similar comorbidities. A theoretically informed, practical, empirically grounded approach will systematically unpack CBT's working mechanisms, clarify for whom it works, ease dissemination, appeal to patients, providers, payers, and policy makers in the COVID-19 era favoring low resource intensity treatments, and reduce cost and inefficiencies associated with high intensity therapies whose complexity, length, and scarcity restricts uptake and impact.

NCT ID: NCT05127226 Active, not recruiting - Angelman Syndrome Clinical Trials

HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome

Start date: December 22, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of ascending doses of ION582 administered intrathecally in participants with Angelman syndrome.

NCT ID: NCT05126914 Not yet recruiting - Epilepsy Clinical Trials

Multicentre Real-life Follow-up Study of Rare Epileptic Syndromes in Children and Adolescents

EPIRARE
Start date: December 2021
Phase:
Study type: Observational

Rare epilepsies as a whole account for 20-30% of epilepsies, but knowledge about prognostic factors is currently limited. This means that it is difficult to provide adequate information to families at diagnosis and during follow-up. Prognostic factors are also important for management as they can have an impact on the patient's outcome (time to intervention, choice of one molecule over another, etc.). Finally, few treatments are currently available for these epilepsies. One of the limitations to the development of treatments is the lack of real life data as it is difficult to create reliable primary endpoints such as the rate of patients becoming seizure free naturally compared to a therapeutic intervention. The aim of this real-life study is to evaluate the response to treatment as well as to see the evolution of cognitive and psychiatric comorbidities. As explained above, there are very few randomised trials except for 3 rare epilepsies (infantile spasm syndrome, Dravet syndrome, Lennox-Gastaut syndrome). This has led to the virtual absence of management recommendations, including for the three syndromes mentioned above, where attempts at treatment algorithms have been proposed, although these have not been able to be considered as evidence-based recommendations. As a result, there is some diversity in the management of rare epilepsies from one centre to another. However, this diversity in management can be an asset in a real-life study. This will make it possible to compare different management methods, both in terms of seizure control and medium-term outcome.

NCT ID: NCT05126888 Not yet recruiting - Tourette Syndrome Clinical Trials

SCI-110 in the Treatment of Tourette Syndrome

Start date: February 2024
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy, safety and tolerability of the cannabinoid-based medication SCI-110 compared to placebo in subjects with Tourette syndrome.

NCT ID: NCT05126563 Completed - Clinical trials for Post COVID-19 Syndrome

Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome

HBPCOVID02
Start date: January 6, 2022
Phase: Phase 2
Study type: Interventional

This study will enroll up to 80 subjects with Chronic Post COVID-19 Syndrome. Subjects will receive four intravenous injections of either allogeneic HB-adMSC's or a placebo over 10 weeks with two follow-up visits and an end of study visit at week 26.

NCT ID: NCT05126043 Completed - Clinical trials for Acute Coronary Syndrome

Lipid Profile in Acute Coronary Syndrome

Start date: November 30, 2021
Phase:
Study type: Observational

This study aims to assess the TG/Hdl-c ratio in patients with acute coronary syndrome as a novel marker of atherosclerosis.

NCT ID: NCT05125419 Completed - Clinical trials for Acute Coronary Syndrome

Homocysteine in Acute Coronary Syndrome

Start date: November 30, 2021
Phase:
Study type: Observational [Patient Registry]

This study aims to determine the relation between high homocysteine levels and increased incidence of acute coronary syndrome in young patients

NCT ID: NCT05125276 Recruiting - Clinical trials for Non ST Segment Elevation Acute Coronary Syndrome

Less Bleeding by Omitting Aspirin in Non-ST-segment Elevation Acute Coronary Syndrome Patients

LEGACY
Start date: May 13, 2022
Phase: Phase 4
Study type: Interventional

Rationale: Dual antiplatelet therapy, consisting of aspirin and a P2Y12-inhibitor, reduces the risk of stent thrombosis, myocardial infarction and stroke after coronary stent implantation. Inevitably, it is also associated with a higher risk of (major) bleeding. Given the advances in stent properties, stenting implantation technique and pharmacology, it may be possible to treat patients with a single antiplatelet strategy by completely omitting aspirin. Objective: This study will assess whether omitting aspirin reduces the rate of major or minor bleeding while remaining non-inferior to the current standard of care with regards to ischemic events in patients with non-ST segment elevation acute coronary syndrome. Study design: Open-label, multicentre randomized controlled trial. Study population: Adult patients presenting with non-ST segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. Intervention: In the intervention group aspirin will be completely omitted from the antiplatelet regimen in the 12 months following PCI. Main study endpoints: The primary bleeding endpoint is major or minor bleeding defined as Bleeding Academic Research Consortium type 2, 3 or 5 bleeding at 12 months. The primary ischemic endpoint is ischemic events defined as the composite of all-cause death, myocardial infarction and stroke at 12 months.

NCT ID: NCT05125263 Completed - Clinical trials for Patellofemoral Pain Syndrome

Effects of Kinesiotaping and Mulligan Tapping on PFPS

Start date: November 15, 2021
Phase: N/A
Study type: Interventional

The aim of this research is to compare the effects of kinesiotaping and mulligan taping on pain, hamstring flexibility, cadence and physical performance of lower limb in patients suffering from patellofemoral pain syndrome according to time duration 24, 48 and 72 hours. Randomized controlled trial done at Riphah International University Rawalpindi campus, Pakistan Railway Hospital and private clinics of twin cities. The sample size was 20. The subjects were divided in two groups, 10 subjects in kinesiotaping group and 10 in mulligan taping group. Study duration was 1 year. Sampling technique applied was non probability convenient sampling technique. Both males and females of 20-35 age bracket having anterior knee pain for more than 2 months and ≥3 pain on NPRS while performing activities i.e. ascending descending stairs, squatting and sitting for extending periods of time were included in study. Tools used in study are NPRS, Kujala pain rating sale, goniometer, active knee extension test, time up and go test.